Chlamydia Infection Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)
|発行||Mordor Intelligence LLP||商品コード||921904|
|出版日||ページ情報||英文 112 Pages
|世界のクラミジア感染症診断市場：成長、動向、および予測（2020年～2025年） Chlamydia Infection Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日: 2020年01月01日||ページ情報: 英文 112 Pages||
Owing to the rising prevalence of chlamydia and major shift from conventional technologies to molecular diagnostics the market studied is growing rapidly. In 2016, WHO estimated 376 million new infections with 1 of 4 being STIs, out of which, the incidence of chlamydia was 127 million, gonorrhea was 87 million, and syphilis was 6.3 million. Furthermore, there is a growing focus on rapid testing since it delivers a quick results. In 2018, the NIBIB-funded researchers authorized a rapid STD test that delivered accurate results in about 30 minutes for chlamydia, allowing patients to receive treatment immediately, thereby curtailing further spread of disease. There is a negative social perception of STDs, as they are caused due to sexual interactions. Hence, people are more conscious about their privacy and social status, when it comes to STD testing, which is limiting the growth of the market studied.
Chlamydia is a curable and common, sexually transmitted infection that may not cause symptoms. It spreads through vaginal, anal, and oral sex. The infection is carried in semen (cum), pre-cum, and vaginal fluids. Chlamydia can infect the penis, vagina, cervix, anus, urethra, eyes, and throat.
Laboratory-Based Tests dominates the Global Chlamydia Infection Diagnostics Market
North America Dominates the Global Chlamydia Infection Diagnostics Market
North America holds a leading position in the Chlamydia Infection Diagnostics market during the forecast period. In 2017, a total of 1,708,569 chlamydial infections were reported to the Centre for Disease Prevention and Control (CDC) in 50 states of the United States. During 2016-2017, the rate of reported cases increased by 6.9%, from 494.7 to 528.8 cases per 100,000 population. The National Health and Nutrition Examination Survey (NHANES) is a nationally representative survey of the US civilian, a non-institutionalized population that provides an important measure of chlamydia disease burden in respondents aged 14-39 years. In March 2019, USFDA granted clearance to diagnostic tests for extragenital testing for chlamydia and gonorrhea, Aptima Combo 2 Assay, to Hologic Inc. and Xpert CT/NG to Cepheid. Hence, the high rate of diagnosis, high adoption and awareness among the people and the introduction of new and technologically advanced tests are also contributing to the growth of the market in North America.
Currently, many private pharmaceuticals and biotechnology companies drive, direct and coordinate the development and introduction of novel products into the market which is easily affordable and accessible. Some of the key innovations in the market are: In July 2019, Nurx, the San Francisco-based startup launched three new test kits, which will test for conditions such as chlamydia, gonorrhea and syphilis.